Observational studyRespiratory research2026
Identification of clinical-biological endophenotypes in patients with eosinophilic granulomatosis with polyangiitis using unsupervised machine learning: a real-world study.
Observational study in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by high clinical heterogeneity. The conventional binary classification based on antineutrophil cytoplasmic antibody (ANCA) status inadequately captures this heterogeneity and provides limited guidance for individualised treatment decisions. This study aimed to identify and validate clinical-biological endophenotypes in EGPA using unsupervised machine learning methods based on multidimensional real-world clinical data, to inform precision medicine approaches.
methodsIn this retrospective single-centre observational study, we included 205 patients diagnosed with EGPA between January 2015 and December 2023 at China-Japan Friendship Hospital. Comprehensive data on demographics, clinical manifestations, laboratory tests, imaging features, and treatment information were systematically collected. Consensus clustering combined with K-means algorithm was applied to identify patient subgroups based on 14 core features, including peripheral blood eosinophil count, fractional exhaled nitric oxide (FeNO), serum total IgE, C-reactive protein (CRP), ANCA status, and multi-system involvement. Principal component analysis was used for dimensionality reduction and visualisation. Differences in clinical characteristics, laboratory parameters, imaging patterns, and treatment responses were compared among the subgroups. An online prediction tool was developed and validated based on the clustering results.
resultsConsensus clustering analysis identified three stable endophenotypes (optimal cluster number k = 3). Subgroup 1 (n = 78, 38.0%): Eosinophilic-Airway Inflammation Type, characterized by markedly elevated eosinophil count (6.10 × 10⁹/L, IQR: 5.10-8.00), FeNO (79 ppb, IQR: 55-112) and serum total IgE (798 IU/mL, IQR: 602-980), predominant respiratory symptoms, with ground-glass opacities and consolidation as main findings on chest high-resolution computed tomography, and among patients who received mepolizumab, a partial remission rate of 89.7% was observed. Subgroup 2 (n = 65, 31.7%): ANCA-Systemic Vasculitis Type, defined by a significantly higher ANCA positivity rate (26.2%) compared to the other subgroups, significant systemic inflammatory response (CRP: 33.5 mg/L, IQR: 22.5-48.5) and frequent peripheral nervous system involvement (76.9%), receiving higher initial glucocorticoid doses. Subgroup 3 (n = 62, 30.2%): Paucieosinophilic-Multi-Organ Damage Type, presenting with relatively low eosinophil-related indices but higher proportions of skin, gastrointestinal, and cardiac involvement, commonly showing fibrotic changes on imaging, and with a numerically lower observed overall response rate to available biologics (51.6%). The developed online prediction tool showed good performance in an independent validation cohort (overall accuracy 90.0%, Kappa agreement with expert judgement 0.850).
conclusionUsing unsupervised machine learning on real-world data, this study successfully identified three distinct clinical-biological endophenotypes in EGPA, revealing different underlying pathophysiological mechanisms and treatment response patterns, and developed a clinically translatable prediction tool. This endophenotype framework and tool may help inform individualised treatment strategies and provide an exploratory data-driven classification basis and decision support for future precision medicine research in EGPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.